stockrowZimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.
- Revenue
- +3.07%
- EPS
- −13.5%
- Free cash flow
- +29.8%
- Total debt
- −7.50%
Quarter to September 2026, against a year earlier
Follow ZBH
Alert me
Zimmer Biomet Holdings, Inc. (ZBH) EPS (diluted)
Zimmer Biomet Holdings, Inc.'s EPS (diluted) for fiscal 2025 was $3.55, down 19.9% from $4.43 in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.96. Over the past ten years it has ranged from −$1.86 (fiscal 2018) to $9.03 (fiscal 2017); the current reading is higher than 64% of that period. Zimmer Biomet Holdings, Inc. ranks 11th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $3.55 | (19.86%) |
| FY2024 | $4.43 | (9.22%) |
| FY2023 | $4.88 | 343.64% |
| FY2022 | $1.10 | (42.41%) |
| FY2021 | $1.91 | — |
| FY2020 | −$0.67 | — |
| FY2019 | $5.47 | — |
| FY2018 | −$1.86 | — |
| FY2017 | $9.03 | 502.00% |
| FY2016 | $1.50 | 94.73% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.01 | (2.16%) |
| Jun 2026 | $1.03 | (15.57%) |
| Mar 2026 | $1.22 | 74.29% |
| Dec 2025 | $0.70 | (39.66%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| STE STERIS plc compare | $8.43 |
| PODD Insulet Corporation compare | $6.14 |
| GMED Globus Medical, Inc. compare | $4.07 |
| PEN Penumbra, Inc. compare | $3.97 |
| ZBH Zimmer Biomet Holdings, Inc. | $3.96 |
| DXCM DexCom, Inc. compare | $2.55 |
| PHG Koninklijke Philips N.V. compare | $1.17 |
| SNN Smith & Nephew SNATS, Inc. compare | $1.13 |
| GKOS Glaukos Corporation compare | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ZBH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement